Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

JU INSIGHT Diagnostic 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence

By: Ashesh B. Jani, MD, Winship Cancer Institute of Emory University, Atlanta, Georgia; Gregory C. Ravizzini, MD, The University of Texas MD Anderson Cancer Center, Houston; Benjamin A. Gartrell, MD, Montefiore Medical Center, Bronx, New York; Barry A. Siegel, MD, Mallinckrodt Institute of Radiology and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri; Przemyslaw Twardowski, MD, John Wayne Cancer Institute, Santa Monica, California; Daniel Saltzstein, MD, Urology San Antonio, Texas; Mark T. Fleming, MD, Virginia Oncology Associates, US Oncology Research, Norfolk; Albert Chau, MSc, CStat, Blue Earth Diagnostics Ltd, Oxford, United Kingdom; Phillip Davis, MD, Blue Earth Diagnostics Inc, Monroe Township, New Jersey; Brian F. Chapin, MD, The University of Texas MD Anderson Cancer Center, Houston; David M. Schuster, MD, Emory University, Atlanta, Georgia On behalf of the SPOTLIGHT Study Group | Posted on: 30 Aug 2023

Jani AB, Ravizzini GC, Gartrell BA, et al. Diagnostic performance and safety of 18F-rhPSMA-7.3 positron emission tomography in men with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT). J Urol. 2023;210(2):299-311.

Study Need and Importance

Radiohybrid (rh) 18F-rhPSMA-7.3 is a novel high-affinity prostate-specific membrane antigen—targeted positron emission tomography (PET) radiopharmaceutical in development for diagnostic imaging of prostate cancer. 18F-rhPSMA-7.3 has lower than average urinary excretion reported for the existing prostate-specific membrane antigen ligands, which may enhance visualization of the prostate region. This phase 3, multicenter, open-label study was conducted to evaluate the diagnostic performance of 18F-rhPSMA-7.3-PET for localization of recurrent prostate cancer as read by 3 blinded central readers.

What We Found

18F-rhPSMA-7.3 was well tolerated and provided a high overall detection rate (83%) among 389 patients with biochemically recurrent prostate cancer. A standard of truth (SoT; histopathology or confirmatory imaging) verified detection rate (VDR) of 51%-54% across readers was determined, exceeding the prespecified statistical threshold for this coprimary end point. A second coprimary end point, combined region-level positive predictive value, ranged from 46%-60% across readers, not exceeding the threshold. Notably, both VDR and combined region-level positive predictive value exceeded the statistical thresholds when evaluating a subset of patients with histopathology rather than conventional imaging SoT.


The data are limited by a low frequency of histopathology SoT. SPOTLIGHT employed a rigorous binary imputation method for the primary end points, whereby a PET-positive region not confirmed on imaging or histopathology was categorized as false-positive by default. The predominance of CT, MRI, and bone scans as the SoT likely led to a proportion of PET-positive lesions being categorized as false-positive that would have been categorized true-positive by a more sensitive SoT.

Interpretation for Patient Care

18F-rhPSMA-7.3 has a favorable safety profile and a clinically meaningful VDR. 18F-rhPSMA-7.3-PET provides another diagnostic option that can be used to correctly restage patients with recurrent prostate cancer.